April 26, 2022

To,
The Manager
BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip Code – 532523

To,
The Manager
National Stock Exchange of India Limited
Corporate Communication Department
Exchange Plaza, Bandra Kurla Complex
Mumbai – 400 050
Scrip Symbol – Biocon

Subject: Press Release titled “Biocon Biologics’ Insugen® Awarded a Three-Year Contract by Ministry of Health, Malaysia”

Dear Sir/Madam,

Please find enclosed the press release titled “Biocon Biologics’ Insugen® Awarded a Three-Year Contract by Ministry of Health, Malaysia”.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For Biocon Limited

[Signature]

Mayank Verma
Company Secretary and Compliance Officer

Enclosed: Press Release
PRESS RELEASE

Biocon Biologics’ Insugen® Awarded a Three-Year Contract by Ministry of Health, Malaysia

Bengaluru, Karnataka, India, April 26, 2022 -

Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd., today announced that its subsidiary Biocon Sdn. Bhd. in Malaysia has been awarded a three-year contract, valued at USD 90 million* (MYR 375 million), for its recombinant human insulin brand Insugen®, by the Ministry of Health (MoH), Malaysia.

Biocon Sdn. Bhd. a subsidiary of Biocon Biologics in Malaysia, will manufacture and supply its range of insulins to its partner Duopharma Marketing Sdn. Bhd. (DMktg), a subsidiary of Duopharma Biotech, a leading pharmaceutical & biotech company in Malaysia.

Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health clinics.

Susheel Umesh, Chief Commercial Officer, Emerging Markets, Biocon Biologics, said: “We are pleased to renew our commitment to provide affordable access to our recombinant human insulin for people with diabetes in Malaysia through this new government contract. This will enable us to serve over 400,000 people with diabetes using recombinant human insulin, helping the government in its journey towards equitable access to diabetes care.”

The rh-Insulin formulations, Insugen®-R, Insugen®-N and Insugen®-30/70, are manufactured at Biocon Sdn. Bhd.’s Johor facility and have been approved by the National Pharmaceutical Regulatory Authority (NPRA), Malaysia.

Biocon Biologics has created a Center of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to manufacture a broad portfolio of regular, basal and rapid insulins. The state-of-the-art insulins facility in Johor, is the first and only biopharmaceutical sterile injectables facility in Malaysia to receive U.S. FDA and EMA approval. More recently, Biocon’s biosimilar insulin Glargine made at Malaysia, has received a historic U.S. FDA approval as the ‘first interchangeable biosimilar’.

Through its scientifically validated, high quality human insulin and analog products manufactured at Malaysia, Biocon Biologics is providing affordable access to these life-
saving therapies to patients in many developed markets like U.S., EU, Australia, as well as many emerging market countries in the Middle East and Latin America.

As a leading global insulins player, Biocon Biologics has provided over 2.75 billion doses of rh-Insulin to patients across the world. The Company is committed to expanding affordable access to high quality insulins for patients and enabling savings for the healthcare systems across the world.

*Values quoted at Ministry of Health prices (value of contract)*

About Biocon Biologics Limited
Biocon Biologics Ltd., a subsidiary of Biocon Ltd., is a unique, fully integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower costs of biologics therapies while improving healthcare outcomes. It has a strong research pipeline of biosimilar molecules across diabetes, oncology, immunology and other non-communicable diseases. Seven molecules from Biocon Biologics’ portfolio have been commercialized in key emerging markets and developed markets like U.S., EU, Australia, Canada, Japan. It has many firsts to its credit including the most recent U.S. FDA approval of the world’s first interchangeable biosimilar, awarded to its Insulin Glargine, which has been commercialized in the U.S. in 2021. Biocon Biologics has signed a strategic alliance with Serum Institute Life Sciences (subject to certain closing conditions) to address the inequitable access to life saving vaccines and biologics globally. With a team of ~5,000 people, Biocon Biologics is committed to transforming healthcare and transforming lives by enabling affordable access to millions of patients’ worldwide. Website: www.bioconbiologics.com; Follow us on Twitter: @BioconBiologics for company updates.

<table>
<thead>
<tr>
<th>BIOCON BIOLOGICS CONTACTS:</th>
<th>INVESTOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEDIA</td>
<td><a href="mailto:nikunj.mall@biocon.com">nikunj.mall@biocon.com</a></td>
</tr>
<tr>
<td>Seema Ahuja</td>
<td>Nikunj Mall</td>
</tr>
<tr>
<td>SVP &amp; Global Head of Communications</td>
<td>Head, Investor Relations</td>
</tr>
<tr>
<td>&amp; Corporate Brand</td>
<td>+91 998 777 4078</td>
</tr>
<tr>
<td>+91 80 2808 2222</td>
<td>Email: <a href="mailto:nikunj.mall@biocon.com">nikunj.mall@biocon.com</a></td>
</tr>
<tr>
<td>+91 99723 17792</td>
<td></td>
</tr>
<tr>
<td>Email: <a href="mailto:seema.ahuja@biocon.com">seema.ahuja@biocon.com</a></td>
<td></td>
</tr>
</tbody>
</table>